Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
Completed
- Conditions
- Vaccines, Pneumococcal Conjugate Vaccine
- Registration Number
- NCT00683410
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
To collect post-marketing information on the safety of Prevenar in Filipino patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3366
Inclusion Criteria
- All patients from the study center who received or will receive at least one dose of Prevenar according to the approved product indication.
Exclusion Criteria
- Previously discontinued Prevenar therapy due to safety concerns.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of Participants With Spontaneous Adverse Events 30 days post injection up to 3 years
- Secondary Outcome Measures
Name Time Method